Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Arcutis Biotherapeutics, Inc. (ARQT : NSDQ)

• Company Description    Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis, atopic dermatitis, seborrheic dermatitis and eczema, which are in clinical stage. Arcutis Biotherapeutics Inc. is based in Westlake Village, California. Number of Employees: 147

• Price / Volume Information    Yesterday's Closing Price: $18.25 Daily Weekly Monthly 20 Day Moving Average: 246,378 shares Shares Outstanding: 51.42 (millions) Market Capitalization: $938.38 (millions) Beta: 0.28 52 Week High: $29.37 52 Week Low: $13.59 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -9.20% -0.51% 12 Week 14.20% 23.92% Year To Date -12.01% 4.64%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2945 TOWNSGATE ROAD SUITE 110 - WESTLAKE VILLAGE,CA 91361 USA ph: 805-418-5006 fax: - ir@arcutis.com http://www.arcutis.com

• General Corporate Information    Officers Todd Franklin Watanabe - President; Chief Executive Officer and Director Patrick J. Heron - Chairman and Director Scott L. Burrows - Chief Financial Officer Bhaskar Chaudhuri - Director Terrie Curran - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 03969K108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 51.42 Most Recent Split Date: (:1) Beta: 0.28 Market Capitalization: $938.38 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.36 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.74 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.08 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -67.11% vs. Previous Quarter: 10.56% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -65.47 12/31/21 - -54.08 09/30/21 - -45.12 ROA 03/31/22 - -57.32 12/31/21 - -48.57 09/30/21 - -42.55 Current Ratio 03/31/22 - - 12/31/21 - 12.09 09/30/21 - 20.03 Quick Ratio 03/31/22 - - 12/31/21 - 12.09 09/30/21 - 20.03 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - - 12/31/21 - 5.92 09/30/21 - 7.22 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - 0.24 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - - 12/31/21 - 19.55 09/30/21 - 0.00

Powered by Zacks Investment Research ©